论文部分内容阅读
目的:探讨普伐他汀对慢性心力衰竭(CHF)患者血浆脑钠素(BNP)水平和心功能的影响。方法:将56例CHF患者随机分为普伐他汀组(30例)和对照组(26例),2组均给予常规治疗,普伐他汀组另加普伐他汀10mg,qn,疗程8周。测定治疗前、后左心室舒张末内径(LVDd)、左心室射血分数(LVEF)、血浆BNP浓度的变化。结果:普伐他汀治疗8周后,血浆BNP浓度由(218.6±64.2)ng/L降至(149.4±50.1)ng/L(P<0.01);LVEF由(34.4±3.4)%升至(45.4±4.9)%(P<0.05),LVDd由(65.5±5.1)mm降至(45.4±4.9)mm(P<0.05),与对照组比较均差异有统计学意义;且患者血浆BNP降低值与LVEF增加存在负相关(r=-0.71,P<0.01),而与LVDd减少呈正相关(r=0.79,P<0.05)。结论:普伐他汀能明显改善心功能,抑制血浆BNP增高。
Objective: To investigate the effects of pravastatin on plasma BNP and cardiac function in patients with chronic heart failure (CHF). Methods: Fifty-six patients with CHF were randomly divided into pravastatin group (n = 30) and control group (n = 26). Both groups were given routine treatment. Pravastatin group plus pravastatin 10 mg qn for 8 weeks. The changes of left ventricular end-diastolic diameter (LVDd), left ventricular ejection fraction (LVEF) and plasma BNP concentration before and after treatment were measured. Results: Plasma BNP levels decreased from (218.6 ± 64.2) ng / L to (149.4 ± 50.1) ng / L after pravastatin treatment for 8 weeks (P <0.01); LVEF increased from (34.4 ± 3.4)% to (P <0.05). The LVDd decreased from (65.5 ± 5.1) mm to (45.4 ± 4.9) mm (P <0.05), and the difference was statistically significant compared with the control group LVEF increased (r = -0.71, P <0.01), but decreased positively with LVDd (r = 0.79, P <0.05). Conclusion: Pravastatin can significantly improve cardiac function and inhibit the increase of plasma BNP.